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Abstract
Purpose Chordoma is a rare but highly aggressive primary bone sarcoma that arises commonly from the sacrum. While en bloc
resection has been the mainstay of the treatment, the role of resection margin in millimetres with/without adjuvant radiotherapy
(RT) has been unknown.We investigated the prognostic impact of surgical margin width, adjuvant RT, and their combined factor
for sacral chordoma.
Methods Forty-eight patients who underwent surgical treatment between 1996 and 2016 were studied. Of these, 11 patients
(23%) received adjuvant RT; photon RT in 7 (15%) and proton RT in 4 (8%). Margins were microscopically measured in
millimetres from the resection surface to the closest tumour on histologic slides.
Results The five year and ten year disease-specific survival was 88% and 58%, respectively, and the local recurrence (LR) rate
was 48%. The LR rate with 0-mm, < 1.5-mm, and ≥ 1.5-mmmargin was 50% (group 1), 50% (group 2: RT−, 61%; group 3: RT+,
14%), and 0% (group 4), respectively. We observed a significantly lower LR rate in patients with adjuvant photon/proton RT
(18%) than without it (57%; p = 0.026), and no LR was observed after post-operative proton RT. The combined factor of margin
with RT clearly stratified the LR risk: patients of group 1 (positive margin) and 2 (< 1.5-mm margin, RT−) had approximately
7.5× LR risk (p = 0.049) compared with those of group 3 (< 1.5-mm margin, RT+) and 4 (≥ 1.5-mm margin).
Conclusion This study identified the lowest risk of local failure in tumour resection with ≥ 1.5-mmmargin or negative but < 1.5-
mm margin with the use of adjuvant photon/proton radiotherapy for sacral chordoma. Early results of adjuvant proton RT
demonstrated excellent local control.
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Introduction
Chordoma is a rare primary bone tumour accounting for 1–4%
of all bone malignancies [1–5], arising in the sacrum (50–
60%), skull base (35%) or vertebral bodies (15%) [5, 6]. En
bloc resection has been the mainstay of the treatment [5,
7–11], although recent evidence has underlined the increasing
role of adjuvant radiotherapy [12–16]. Although chordoma is
histologically characterized as low grade, it is highly recurrent
and aggressive and associated with a poor prognosis [17]. The
reported local recurrence (LR) rate after surgery is 30–75% [4,
11], and five and ten year overall survival (OS) rates are 70–
86% [13, 14, 18, 19] and 35–59% [7, 9, 19–23], respectively.
To date, several prognostic factors influencing local control
and survival have been reported: age (LR-free survival
[LRFS] [24]; OS [21, 25]), location (LRFS [19, 24]; OS [19,
25, 26]), surgical margin (LRFS [5, 7–10, 21, 26, 27]; OS [21,
27]), size (OS [10, 27]), volume (LRFS [9, 26]; OS [26]),
micro-skip metastasis (LRFS [11]), vascular invasion (OS
[11]), and previous diagnostic/surgical procedure (LRFS [22,
26]). Despite the discrepancy among previous studies in terms
of the prognostic factor, most of these publications described
resection margin a crucial factor among the others.
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There is no consensus on how surgical margins for bone
and soft-tissue sarcomas are reported among different insti-
tutes worldwide, with most of the existing investigations hav-
ing been performed on the system of Enneking et al.:
intralesional, marginal, wide, and radical [28]. In addition,
the interpretation of what is a marginal and wide resection
remains inherently subjective and may vary depending on
the investigators [29]. The adoption of a simple system incor-
porating measurable and reproducible variables would allow
standardisation of treatment and monitoring and reduce bias.
The closest surgical margin in millimetres could replace any
subjective methods of surgical margin. Recently, the
Birmingham classification for osteosarcoma, devised on the
bases of the margin in millimetres and the response of chemo-
therapy, was superior to the conventional margin classification
by Enneking for predicting LR [29]. The predictive role of
margins in mil l imetres was also invest igated in
chondrosarcoma, which clearly stratified LRFS between
groups in all histological grades with a surgical margin of >
4 mm [30]. However, no study has investigated the role of
surgical margin in chordoma with a focus on the closest mar-
gin in millimetres.
The efficacy of adjuvant radiotherapy for sacral chordoma
remains controversial [12, 13, 31–33]. Several retrospective
studies at a single institution demonstrated that neo-adjuvant
and/or adjuvant radiotherapy in combination with surgical re-
section led to better local relapse-free survival than surgical
treatment alone [12, 13, 32, 33]. Conversely, a recent
multicentre study reported that radiotherapy was not associat-
ed with local disease control, but it was associated with com-
plications [31]. These inconsistencies might be attributed to
the unstandardized treatment paradigms among multiple insti-
tutions, such as timing of treatment (pre- or post-operative),
type of radiotherapy (photon, proton, or carbon ion), and ra-
diation dose. Notably, the benefits of proton radiotherapy in an
adjuvant setting have been unclear [34–36], while carbon ion
[15, 18, 37] or proton radiotherapy [12, 15, 18, 38] plays a role
in unresectable cases.
In the era of modern multidisciplinary treatment, prognos-
tic risk prediction based on a single treatment-related factor
may not provide precise information. We hypothesised that an
approach combining surgical margin and the use of adjuvant
radiotherapy might provide more precise prognostic risk strat-
ification. The purpose of this study was to investigate the
prognostic role of surgical margin width, adjuvant radiother-
apy, and the combined factor of these in patients with sacral
chordoma.
Patients and methods
We conducted a retrospective study of patients with sa-
cral chordoma who underwent surgical treatment
between 1996 and 2016 at a single institution. During
this period, a total of 82 consecutive patients were di-
agnosed with a chordoma and 61 of these underwent
surgical resection as initial treatment, excluding those
who were treated with definitive radiotherapy, treated
palliatively, and initially treated elsewhere and referred
for the management of a recurrence. Patients with
chordoma arising from sites other than the sacrum,
those with minimum follow-up less than two years for
patients alive, and those whose resection margin in
millimetres was unavailable were also excluded.
Details of the clinical data which were collected from
the notes included age at diagnosis, sex, tumour site, tu-
mour size, level of resection, details of operations, surgi-
cal margin, pathological reports, and oncological out-
come. Tumour volume was measured on histopathologic
specimens or on coronal, transverse, and sagittal magnetic
resonance (MR) imaging of the lesion; the volume was
calculated using the formula of an ellipsoid mass volume:
(π/6) × height × width × depth [26]. Margins were micro-
scopically measured in millimetres from the resection sur-
face to the closest tumour on histologic slides following
gross examination of the specimen by pathologists highly
experienced in bone and soft-tissue sarcomas.
Histological diagnosis was pre-operatively confirmed
and a treatment plan was discussed at a multidisciplin-
ary meeting for all patients. The surgical indications
were determined under considerations for the location
and size of the lesion, its potential margins, absence
of metastatic disease at presentation, the predicted sur-
gical morbidity and mortality, and the patient's prefer-
ence. For tumours at or below S3 level, resections were
performed through a posterior approach, whereas tu-
mours at S1/2 levels were resected using a combined
anterior and posterior approach [5]. Depending on the
cases, a vertical rectus abdominis myocutaneous flap
was used to fill the dead space after tumour resection.
Radiotherapy was considered in the postoperative setting
if the resection margin was marginal or intralesional but
also considered regardless of the margin width since
2014. Proton radiotherapy was recommended since
2012, due to the proximity of the rectum and side ef-
fects of external beam radiotherapy. Decision on the use
of radiotherapy was made according to the post-
operative local conditions such as wound healing after
a multidisciplinary team discussion.
Post-operatively, patients remained on bed rest for the first
five days. Following review of the wound, they were
mobilised fully weight bearing under the guidance of a phys-
iotherapist. Routine follow-up for patients was performed ev-
ery three months for the first two years, every six months for
the next three years, and then annually thereafter unless the
patient developed new symptoms. Patients underwent spinal
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MR imaging at each visit and a chest radiograph annually for
the screening of pulmonary metastases.
Disease-specific survival and local recurrence-free
survival were analysed using the Kaplan-Meier analysis.
Disease-specific survival was defined as the period from
the date of diagnosis to the last date when the patient
was recorded to be alive or the date of tumour-related
death. LRFS was defined as the period from the date of
treatment and censored at the date of LR. The variables
of each group were compared using the chi-square test,
Student t test, or Mann-Whitney U test. All statistical
analyses were performed using the SPSS software (ver-
sion 23; IBM, Armonk, New York, USA). Differences
were considered to be statistically significant at a p
value < 0.05.
Results
Patient characteristics
After exclusion criteria, a total of 48 patients were available
for analysis. The patient demographics and therapies are
summarised in Table 1. The mean age at diagnosis was
61 years (range, 16 to 86 years) with a slight male predomi-
nance (n = 28; 58%). The mean tumour size was 9.3 cm
(range, 3.0 to 17.5 cm), and the mean tumour volume was
347 cm3 (range, 5 to 2136 cm3). The highest level of tumour
was at S1 in seven patients (14.5%), S2 in 7 (14.5%), S3 in 12
(25%), S4 in 12 (25%), S5 in six (13%), and coccyx in four
(8%). Of 48 patients who underwent surgical treatment, 11
patients (23%) received post-operative radiotherapy.
Table 1 Univariate analysis for local recurrence-free survival and disease-specific survival
Variables No. of patients %, range LRFS DSS
% (5-year) p value % (5-year) p value
Total 48 – 48% – 88% –
Age (mean, 61 years) 0.224 0.929
< 60 years 16 33% 29% 94%
≥ 60 years 32 67% 59% 84%
Sex 0.677 0.673
Male 28 58% 50% 85%
Female 20 42% 41% 95%
Tumour size (mean, 9.3 cm) 0.160 0.524
< 8 cm 34 71% 54% 89%
≥ 8 cm 14 29% 30% 86%
Tumour volume (mean, 347 cm3) 0.003 0.900
< 205 cm3 21 44% 76% 95%
≥ 205 cm3 27 56% 25% 84%
Highest level of tumour involvement 0.271 0.045
Above S3 14 29% 36% 75%
At or below S3 34 71% 52% 97%
Bone resection level 0.200 0.105
Above S3 20 42% 37% 77%
At or below S3 28 58% 53% 96%
Adjuvant treatment for primary tumour 0.045 0.577
None 37 77% 37% 89%
Radiotherapy (adjuvant) 11 23% 82% 75%
Presence of dedifferentiation 0.104 0.418
Yes 2 4% 0% 10%
No 46 96% 49% 88%
Presence of micro-satellite lesion 0.526 0.347
Yes 3 6% 67% 100%
No 45 94% 45% 88%
Presence of vascular invasion 0.201 0.618
Yes 2 4% 100% 50%
No 46 96% 43% 100%
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Histological investigation identified micro-satellite lesion in
three (6%) and vascular invasion in two (4%). The mean
follow-up period was 77 months (range, 8 to 206 months).
The role of surgical margin in local control
The surgical margins measured in millimetres are shown in
Table 2. The closest margins were observed at the anterior
resections in 27 patients (56%), posterior resections in ten
(21%), lateral resections in seven (15%), and superior resec-
tions in four (8%). The overall LR rate was 48% (n = 23). The
mean duration from primary surgery to LR was 22.4 months
(range, 3 to 52months). LR-free survival was 46% at both five
and ten years. The relationship of the closest margin
in millimetre and LR is shown in Table 2. All of the LRs were
observed in patients with a margin below 1.5 mm; hence, this
was chosen as our cut-off for further analysis. Univariate anal-
ysis revealed that a larger tumour volume (over 205 cm3) and
the use of adjuvant radiotherapy were positive factors for LR
(Table 2). The surgical margin width below 1.5 mm did not
significantly stratify the LRFS (p = 0.104; Supplementary
Fig. 1).
The role of adjuvant radiotherapy in local control
The LR rate was significantly lower in patients with post-
operative radiotherapy (18%) than those without it (57%;
p = 0.026; Table 3) as described. The five year LRFS in pa-
tients with and without post-operative radiotherapy was 82%
and 37%, respectively (p = 0.045; Table 1, Supplementary
Fig. 2A). We observed no LR in patients who underwent
post-operative proton radiotherapy, while two of seven pa-
tients (29%) had LR after post-operative conventional photon
radiotherapy (p = 0.053; Table 2, Supplementary Fig. 2B).
Combined risk stratification in local control according
to surgical margin and adjuvant radiotherapy
The relationship between margin width in millimetres and LR
stratified by post-operative radiotherapy is shown in Table 2.
When we focus on the patients with close margin below
1.5 mm, there was a significant difference in LR rate in pa-
tients with and without radiotherapy (61% and 14%, respec-
tively; p = 0.033). We then divided patients into four groups
based on the combined factor of margin and adjuvant radio-
therapy: group 1, intralesional margins; group 2, margins less
than 1.5 mm without post-operative radiotherapy; group 3,
margins less than 1.5 mm with post-operative radiotherapy;
and group 4, margins over 1.5 mm (Table 4). The LR rate was
57%, 56%, 14%, and 0%, respectively (p = 0.048; Table 4).
Although LRFS was not statistically stratified among these
four groups because of the limited number of patients in each
(p = 0.102; Fig. 1), the combination of these groups (group
1 + 2 vs 3 + 4) demonstrated a significant difference in the
incidence of LR between high and low risk of local failure
(p = 0.013; Fig. 2a), suggesting that obtaining a clear margin
with the addition of radiotherapy is crucial for local control.
Table 2 The margin in millimetres and local recurrence according to the use of postoperative radiotherapy (RT)
Closest margin Total RT− RT+
No. LR+ LR
−
%LR No. LR+ LR
−
%LR No. LR+ LR
−
%LR
0 mm 4 2 2 50% 2 1 1 50% 2 1 1 50%
< 0.1 mm 1 1 0 100% 1 1 0 100% – – – –
0.1 mm 5 0 5 0% 4 0 4 0% 1 0 1 0%
0.5 mm 11 5 6 45% 8 4 4 50% 3 1 2 33%
0.6 mm 1 1 0 100% 1 1 0 100% – – – –
< 1 mm 11 9 2 82% 11 9 2 82% – – – –
1 mm 11 5 6 45% 8 5 3 63% 3 0 3 0%
1.5 mm 2 0 2 0% 1 0 1 0% 1 0 1 0%
3 mm 1 0 1 0% 1 0 1 0% – – – –
5 mm 1 0 1 0% – – – – 1 0 1 0%
Total 48 23 25 48% 37 21 16 57% 11 2 9 18%
Table 3 The use of post-operative radiotherapy and local recurrence
Post-operative radiotherapy Total LR %LR
Yes No
No 37 21 16 57%
Yes 11 2 9 18%
Photon 7 2 5 29%
Proton 4 0 4 0%
Total 48 23 25 48%
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Multivariate analysis revealed that tumour volume (≥ 205 cm3
hazard ratio [HR], 3.746; 95% confidence interval [CI],
1.383–10.141; p = 0.009 versus < 205 cm3 HR, 1) and the
combined factor of surgical margin and the use of adjuvant
radiotherapy (group 1 + 2 HR, 7.502; 95% CI, 1.008–55.837;
p = 0.049 versus group 3 + 4 HR, 1) were independent prog-
nostic predictors for LRFS.
Predictors of disease-specific survival
The disease-specific survival rate was 88% at 5 years and 58%
at 10 years. Univariate analysis revealed that the highest level
of tumour involvement above S3 (p = 0.045) was a negative
prognostic factor. The use of adjuvant radiotherapy was not a
prognostic factor for disease-specific survival, but the patients
treated with adjuvant proton radiotherapy are all alive with a
mean follow-up period of 45months (range, 27 to 81months).
Although the combined factor of surgical margin and post-
operative radiotherapy was not a significant prognostic factor
for disease-specific survival (p = 0.157), we observed a trend
toward better prognosis in patients with group 3 + 4 (Fig. 2b).
None of these factors achieved statistical significance in mul-
tivariate analysis because of the limited number of patients.
Discussion
It is well known that surgical margin remains a crucial prog-
nostic factor for sacral chordoma; however, previous literature
has described margins by the Enneking system (intralesional,
marginal, or wide) [28] or R classification (intralesional or
clear) [39]. Importantly, a surgical margin defined as wide
and marginal varies depending on the reporter and not fully
reproductive [29]. This study is the first to describe the role of
margin width in millimetres for sacral chordoma. Obtaining a
wide margin greater than 1.5 mm is technically demanding for
this disease because of the anatomical proximity to the rectum,
which was confirmed in this study. Therefore, it is important
to stratify and predict the oncologic risk especially for patients
with a close margin below 1.5 mm. We propose the adoption
of a simple system incorporating measurable and reproducible
variables, replacing the subjectivity of ‘wide’, ‘marginal’, or
‘microscopic tumour at margin’ , which will allow
standardisation of treatment and improve communication
and future research.
The role of adjuvant radiotherapy for sacral chordoma re-
mains a subject of debate, and its value in local control is
inconclusive [4, 8, 21, 27, 31, 33]. In this study, we identified
a significantly lower LR rate in patients who received adju-
vant radiotherapy (18%) than in those who did not (57%). Our
results were consistent with those by van Wulfften et al. [33].
In a multicentre study, Houdek et al. reported no significant
benefit by neo- and/or adjuvant radiotherapy but suggested
that this might be attributed to no standardised treatment strat-
egy existing among multiple institutions including regarding
radiation dose, field, or indication [31]. Our study was based
on the results of post-operative radiotherapy, which we be-
lieve would provide useful information based on the safer
use of radiotherapy. Further research involving larger cohorts
with less bias of therapeutic details would be necessary to
Table 4 Cox regression model based on the surgical margin and the use of post-operative radiotherapy for local recurrence-free survival
Classification LR rate LRFS (5-year) p value LRFS (5-year) HR 95% CI p value
Group A 35.1% 7.502 1.008–55.837 0.002
1: margins = 0 mm 50% 50.0% 0.128
2: margins < 1.5 mm without postop RT 61% 32.8% 0.053
Group B 90.9% Reference – –
3: margins < 1.5 mm with postop RT 14% 85.7% 0.450
4: margins ≥ 1.5 mm 0% 100% Reference
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Fig. 1 Kaplan-Meier curves showing local recurrence-free survival strat-
ified by the combined factor with resection margins in millimetres and
adjuvant radiotherapy: 0 mm, 0 mm<margin < 1.5 mm, and margin ≥
1.5 mm (p = 0.102, log-rank test)
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clarify the benefits of the use of radiotherapy for sacral
chordoma.
The effect of proton radiotherapy in an adjuvant setting
has been unclear, whereas recent studies have reported
favourable early results with proton radiotherapy as defin-
itive treatment, with local control rates of over 90% at
3 years [15, 19]. As an adjuvant treatment, proton radio-
therapy was reported to result in a local control rate of
33–95% with a relatively short follow-up (Table 5) [15,
19, 34, 35, 38]. The wide range of local control rates
among these studies might be attributed to the heteroge-
neous settings among the study cohorts, such as margin
status and pre-/postoperative use of proton radiotherapy,
which hinder effective comparisons of the outcomes asso-
ciated with the adjuvant use of conventional photon radio-
therapy [40]. In a multicentre study by Houdek et al.,
there was no association between local control and the
use of proton radiotherapy [31]. However, the authors
postulated that this outcome might be related to the insuf-
ficient number of patients in specific subsets. In the cur-
rent study, we found excellent local control with the use
of adjuvant proton radiotherapy despite the relatively
short follow-up period in patients with negative resection
margins. Further investigation with longer follow-up is
necessary to elucidate the effects of adjuvant proton
radiotherapy.
Regardless of the use of adjuvant radiotherapy,
intralesional resection was associated with a high rate
of LR, as described in a number of previous publica-
tions. In this study, we identified that the LR rate in
patients with a clear but close margin below 1.5 mm
was worse (61%) than that of intralesional margins
(50%) without adjuvant radiotherapy. However, the LR
decreased to 14% in patients with a clear but close (<
1.5 mm) margin when adjuvant radiotherapy was ad-
ministered. These data indicated that the risk of local
failure with narrow margins (< 1.5 mm) may be sal-
vaged by adjuvant radiotherapy. Although we identified
no LR in patients with a margin over 1.5 mm, we
cannot determine the necessity of adjuvant radiotherapy
for them because of the limited numbers and follow-up
periods. Considering the possible presence of a micro-
satellite lesion and the reported LR rate even in the
patients with a wide margin over 1.5 mm [41, 42],
adjuvant radiotherapy could be effective regardless of
the margin extent.
In the era of multidisciplinary treatment for sarcomas,
we face the limitation in risk assessment only by the
single clinicopathological factor. A recent study has dem-
onstrated that more precise risk stratification is achieved
by combining two prognostic factors in patients with
osteosarcoma. The best predictor of LR was the combi-
nation of a resection margin of ≤ 2 mm and a chemother-
apy response of < 90% necrosis compared with a single
factor of either resection margin or response to chemo-
therapy [29]. In this study, clear stratification in LR was
possible using the combined factor of margin in
millimetres and adjuvant radiotherapy, which was impos-
sible only by the surgical margin. This was attributed to
not a small number of patients with clear but close mar-
gin below 1.5 mm, indicating the importance of risk
stratification with the use of adjuvant radiotherapy
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among these patients. Collectively, the combination of
the key therapeutic factors could provide more precise
information for the prognostic prediction and help in
the decision-making of further treatment.
We acknowledge several limitations of this study.
First, data on the quality of surgical margin were not
available but further analysis considering margin quantity
would provide a more accurate prognostic indicator. If
the margin quality could be predicted prior to resection,
particularly when the resection may require close dissec-
tion or even the excision of nearby vital structures, it
may be possible to give more accurate information for
preoperative planning. Second, the follow-up periods in
patients with adjuvant radiotherapy, especially with pro-
ton radiotherapy, were relatively short, despite no statis-
tical difference among them. Longer follow-up for them
would further determine the efficacy of postoperative
photon/proton radiotherapy. Third, this study was
retrospective in nature and was based on the records of
the patients at a single institution. Further well-designed,
retrospective studies with a larger cohort would be useful
for decision-making of treatment. Despite these limita-
tions, we believe that our analyses, which first demon-
strate the role of margin in millimetres in combination
with the use of adjuvant radiotherapy, provide more pre-
cise oncological prediction and help physicians and pa-
tients in making informed decisions of treatments and
follow-ups.
In summary, the present study identified the lowest risk of
local failure in tumour resection with ≥ 1.5 mm margin and
adjuvant photon/proton radiotherapy for sacral chordoma. In
patients with clear margin but narrower than 1.5 mm, risk of
LR is as high as those with the intralesional margin unless
adjuvant radiotherapy is performed. Although longer follow-
up is required, early results demonstrated the excellent local
control by adjuvant proton radiotherapy.
Table 5 Summary of the literature showing the outcomes in patients with sacral chordoma who underwent photon/proton radiotherapy
Author Year N Location
(chordoma)
Treatment Surgical
margin
Outcome Follow-up period
(months)
Refs
Chen 2013 24 Mobile
spine = 5
Sacrum = 19
Definitive photon/proton
RT
– LRFS: 90.4% (3-year), 79.8% (5-year)
MFS: 86.5% (3-year), 76.3% (5-year)
DSS: 90.4% (3-year), 79.8% (5-year)
56 (median) [18]
Mima 2014 23 Sacrum = 23 Definitive proton RT = 7
Definitive carbon
ion = 16
– LRFS: 94% (3-year)
OS: 83% (3-year)
PFS: 68% (3-year)
38 (median) [15]
Boriani 2006 52 Mobile
spine = 48
Sacrum = 0
Surgery = 141
Surgery + photon
RT = 242
Photon RT + palliative
surgery = 103
1R0 = 10,
R1/2 = 4
2R1/2 = 16,
NR = 8
3R1/2 = 10
1LR: 43%, NED: 54%, DOD: 7%
2LR: 67%, NED: 38%, DOD: 38%
3LR: 100%, NED: 0%, DOD 100%
NR [37]
Delaney 2014 50 Mobile
spine = 23
Sacrum = 27
Surgery + pre/post
photon/proton RT
R0 = 8
R1 = 17
R2 = 13
Primary case; LR: 1/23 (4%)
Recurrent case; LR: 3/6 (50%)
R0; LR: 0/7 (0%), R1; 1/10 (10%), R2;
1/3 (33%)
88 (median) [33]
Rotondo 2015 127 Mobile
spine = 56
Sacrum = 71
Surgery + postop proton
RT1 = 58
Surgery + pre/postop
proton RT2 = 60
Definitive proton RT = 93
R0 = 34
R1 = 57
R2 = 30
Primary case
1LRFS (5-year): 56%, DCR (5-year):
82%, OS (5-year): 80%
2LRFS (5-year): 85%, DCR (5-year):
78%, OS (5-year): 85%
Recurrent case
1LRFS (5-year): 44%, DCR (5-year):
57%, OS (5-year): 83%
2LRFS (5-year): 47%, DCR (5-year):
92%, OS (5-year): 71%
3LRFS (5-year): 56%, DCR (5-year):
40%, OS (5-year): 83%
41 (median) [36]
Baumann 2019 20 Skull
base = 10
Mobile
spine = 3
Sacrum = 5
Surgery + proton RT = 17
Definitive proton RT = 2
Proton RT for LR = 1
R0 = 4
R1/R2 = 16
LRFS: 95% (2-year), 86% (3-year)
PFS: 90% (2-year), 81% (3-year)
37 (median) [35]
Abbreviations: LR local recurrence, NED no evidence of disease, DOD dead of disease, LRFS local recurrence-free survival, MFS metastasis-free
survival, DSS disease-specific survival, OS overall survival, DCR distant control rate, PFS progression-free survival, NR not reported
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